Entry

D10316                      Drug

Name

Nivolumab (USAN/INN);
Nivolumab (genetical recombination) (JAN);
Opdivo (TN)

Product

OPDIVO (E.R. Squibb & Sons)

Formula

C6362H9862N1712O1995S42

Exact mass

143509.1148

Mol weight

143597.3811

Sequence

(Heavy chain)
QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV IWYDGSKRYY
ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATND DYWGQGTLVT VSSASTKGPS
VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS
VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT
VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE MTKNQVSLTC
LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV
MHEALHNHYT QKSLSLSLGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H127-L214, H140-H196, H219-H'219, H222-H'222, H254-H314, H360-H418, H'22-H'96, H'127-L'214, H'140-H'196, H'254-H'314, H'360-H'418, L-23-L88, L134-L194, L'23-L'88, L'134-L'194)

Type

Peptide

Class

Antineoplastic
DG02938 Immune checkpoint inhibitor

Remark

Therapeutic category:

4291

ATC code:

L01FF01

Product:

D10316<JP/US>

Product (mixture):

D12334<US>

Efficacy

Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody

Disease

Melanoma [DS:H00038]
Non-small cell lung cancer [DS:H00014]
Small cell lung cancer [DS:H00013]
Malignant pleural mesothelioma [DS:H00015]
Renal cell carcinoma [DS:H00021]
Hodgkin lymphoma [DS:H00007]
Squamous cell carcinoma of the head and neck [DS:H02420]
Urothelial carcinoma [DS:H00022]
Colorectal cancer (MSI-H or dMMR) [DS:H00020]
Hepatocellular carcinoma [DS:H00048]
Esophageal squamous cell carcinoma [DS:H00017]
Gastric cancer [DS:H00018]
Esophageal adenocarcinoma [DS:H00017]

Comment

Monoclonal antibody

Target

PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]

Pathway

hsa04514

Cell adhesion molecules

hsa04660

T cell receptor signaling pathway

hsa05235

PD-L1 expression and PD-1 checkpoint pathway in cancer

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF01 Nivolumab
      D10316  Nivolumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Nivolumab
    D10316  Nivolumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10316  Nivolumab (USAN/INN); Nivolumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10316  Nivolumab
Drug classes [BR:br08332]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10316  Nivolumab
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D10316  Nivolumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D10316
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D10316
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D10316
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D10316
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D10316

Other DBs

CAS:	946414-94-4

PubChem:

163312346